

**February 08, 2024**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai-400051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Subject: Investors Presentation for the Quarter 3<sup>rd</sup> ended on December 31, 2023 of Financial Year 2023-24 – Orchid Pharma Limited (“the Company”)**

Dear Sir/Madam,

In continuation to our earlier intimation letter dated February 05, 2024 regarding the Analysts/ Investors Earning Call scheduled to be held on February 09, 2024 at 05:00 P.M. (IST) and in accordance to the requirement of Regulation 30 of SEBI (Listing Obligation and Disclosures Requirement) Regulations, 2015, please find enclosed the Investor Presentation on the financial highlights of the Company w.r.t the quarter ended on December 31, 2023.

The Investor Presentation is also made available on the website of the Company at [www.orchidpharma.com](http://www.orchidpharma.com)

You are requested to take the above on your record.

Thanking You,  
For **Orchid Pharma Limited**

**Kapil Dayya**  
**Company Secretary & Compliance Officer**

*Encl.: as above*

# Orchid Pharma Limited

Financials Oct-Dec 2023

# Financial Highlights Q3 FY24

**Top line**

38%

**EBIDTA**

92%

**PBT**

355%

**PAT**

355%

\* Compared with 9M FY23

# Financial Highlights


(Rs/Crore)	Q3-2023	Q3-2022	Change %	9M-31 <sup>st</sup> Dec'23	9M-31 <sup>st</sup> Dec'22	Change %
<b>Sales</b>	220.6	159.8	+38%	602.3	456.0	+32%
<b>Other Income</b>	7.4	8.9		17.5	17.7	
<b>COGS</b>	121.9	95.6		356.4	265.7	
<b>Employee Exp</b>	18.7	16.7		52.1	49.0	
<b>Other Exp</b>	44.1	33.8		112.1	97.4	
<b>EBITDA</b>	43.3	22.6	+92%	99.3	61.6	+61%
<b>% to Sales</b>	20%	14%		16%	14%	
<b>Interest</b>	3.5	7.7	-55%	12.9	24.7	-48%
<b>Depreciation</b>	9.3	8.2	+13%	24.8	47.6	-48%
<b>PBT</b>	30.5	6.7		61.6	-10.7	
<b>PAT</b>	30.5	6.7		61.6	-10.7	

# Financial Highlights


Growth Criteria	Q3 23-24	Q2 23-24	Q1 23-24	9ME 23-24
Turnover	38%	20%	40%	32%
EBIDTA	92%	34%	57%	61%
PBT	355%	712%	177%	676%
PAT	355%	712%	177%	676%

\* YoY Comparison with FY23


# Turnover (In Cr.)



# P&L Analysis – Exp. % to sales 9M



# EBITDA & PAT as % to sales 9ME Dec





**Thanks**